ATE323481T1 - Verwendung von propionyl-l-carnitin oder dessen pharmakologisch akzeptabler salze zur herstellung eines medikamentes zur behandlung von la peyronie's krankheit - Google Patents
Verwendung von propionyl-l-carnitin oder dessen pharmakologisch akzeptabler salze zur herstellung eines medikamentes zur behandlung von la peyronie's krankheitInfo
- Publication number
- ATE323481T1 ATE323481T1 AT02793337T AT02793337T ATE323481T1 AT E323481 T1 ATE323481 T1 AT E323481T1 AT 02793337 T AT02793337 T AT 02793337T AT 02793337 T AT02793337 T AT 02793337T AT E323481 T1 ATE323481 T1 AT E323481T1
- Authority
- AT
- Austria
- Prior art keywords
- carnitine
- propionyl
- peyronie
- disease
- treatment
- Prior art date
Links
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 title abstract 4
- 208000004362 Penile Induration Diseases 0.000 title abstract 3
- 208000020758 Peyronie disease Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 abstract 1
- 238000011443 conventional therapy Methods 0.000 abstract 1
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 229960001722 verapamil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001RM000695A ITRM20010695A1 (it) | 2001-11-26 | 2001-11-26 | Uso della propionil l-carnitina o di un suo sale farmacologicamente accettabile per la preparazione di un medicamento per il trattamento del |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE323481T1 true ATE323481T1 (de) | 2006-05-15 |
Family
ID=11455896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02793337T ATE323481T1 (de) | 2001-11-26 | 2002-11-26 | Verwendung von propionyl-l-carnitin oder dessen pharmakologisch akzeptabler salze zur herstellung eines medikamentes zur behandlung von la peyronie's krankheit |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20050038044A1 (de) |
| EP (1) | EP1448184B1 (de) |
| JP (1) | JP4370168B2 (de) |
| KR (1) | KR100923139B1 (de) |
| AT (1) | ATE323481T1 (de) |
| AU (1) | AU2002358991A1 (de) |
| CA (1) | CA2466135C (de) |
| CY (1) | CY1105347T1 (de) |
| DE (1) | DE60210804T2 (de) |
| DK (1) | DK1448184T3 (de) |
| ES (1) | ES2261772T3 (de) |
| HU (1) | HUP0402118A3 (de) |
| IT (1) | ITRM20010695A1 (de) |
| MX (1) | MXPA04004900A (de) |
| PL (1) | PL209317B1 (de) |
| PT (1) | PT1448184E (de) |
| WO (1) | WO2003045373A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8465413B2 (en) | 2010-11-25 | 2013-06-18 | Coloplast A/S | Method of treating Peyronie's disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2658307C2 (de) * | 1976-12-22 | 1979-03-15 | Klinge Pharma Gmbh & Co, 8000 Muenchen | Di-O'-hydroxyphenyD-alkanverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| ATE17746T1 (de) * | 1981-11-18 | 1986-02-15 | Unilever Nv | Raffinieren von fetten. |
| US5038633A (en) * | 1989-09-28 | 1991-08-13 | Kabushiki Kaisha Kobe Seiko Sho | Transmission for mini shovel car |
| IT1283967B1 (it) * | 1996-03-29 | 1998-05-07 | Sigma Tau Ind Farmaceuti | Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi |
| US6069175A (en) * | 1996-11-15 | 2000-05-30 | Pfizer Inc. | Estrogen agonist/antagonists treatment of atherosclerosis |
| IT1290600B1 (it) * | 1997-04-30 | 1998-12-10 | Sigma Tau Ind Farmaceuti | Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio fumarato |
| IT1302858B1 (it) * | 1998-11-11 | 2000-10-10 | Sigma Tau Ind Farmaceuti | Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento avente attivita' antitumorale. |
-
2001
- 2001-11-26 IT IT2001RM000695A patent/ITRM20010695A1/it unknown
-
2002
- 2002-11-26 AT AT02793337T patent/ATE323481T1/de active
- 2002-11-26 JP JP2003546875A patent/JP4370168B2/ja not_active Expired - Fee Related
- 2002-11-26 HU HU0402118A patent/HUP0402118A3/hu unknown
- 2002-11-26 KR KR1020047007881A patent/KR100923139B1/ko not_active IP Right Cessation
- 2002-11-26 US US10/496,659 patent/US20050038044A1/en not_active Abandoned
- 2002-11-26 EP EP02793337A patent/EP1448184B1/de not_active Expired - Lifetime
- 2002-11-26 WO PCT/IT2002/000745 patent/WO2003045373A1/en active IP Right Grant
- 2002-11-26 DK DK02793337T patent/DK1448184T3/da active
- 2002-11-26 CA CA2466135A patent/CA2466135C/en not_active Expired - Fee Related
- 2002-11-26 PL PL371012A patent/PL209317B1/pl unknown
- 2002-11-26 MX MXPA04004900A patent/MXPA04004900A/es active IP Right Grant
- 2002-11-26 ES ES02793337T patent/ES2261772T3/es not_active Expired - Lifetime
- 2002-11-26 DE DE60210804T patent/DE60210804T2/de not_active Expired - Lifetime
- 2002-11-26 PT PT02793337T patent/PT1448184E/pt unknown
- 2002-11-26 AU AU2002358991A patent/AU2002358991A1/en not_active Abandoned
-
2006
- 2006-05-30 CY CY20061100685T patent/CY1105347T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2466135C (en) | 2011-05-31 |
| DE60210804T2 (de) | 2006-10-19 |
| JP4370168B2 (ja) | 2009-11-25 |
| PT1448184E (pt) | 2006-07-31 |
| ITRM20010695A1 (it) | 2003-05-26 |
| PL371012A1 (en) | 2005-06-13 |
| KR100923139B1 (ko) | 2009-10-23 |
| ITRM20010695A0 (it) | 2001-11-26 |
| PL209317B1 (pl) | 2011-08-31 |
| KR20040058316A (ko) | 2004-07-03 |
| DK1448184T3 (da) | 2006-08-21 |
| WO2003045373A1 (en) | 2003-06-05 |
| EP1448184A1 (de) | 2004-08-25 |
| HUP0402118A3 (en) | 2012-09-28 |
| JP2005511638A (ja) | 2005-04-28 |
| EP1448184B1 (de) | 2006-04-19 |
| AU2002358991A1 (en) | 2003-06-10 |
| CA2466135A1 (en) | 2003-06-05 |
| ES2261772T3 (es) | 2006-11-16 |
| DE60210804D1 (de) | 2006-05-24 |
| MXPA04004900A (es) | 2004-08-02 |
| US20050038044A1 (en) | 2005-02-17 |
| CY1105347T1 (el) | 2010-03-03 |
| HUP0402118A2 (hu) | 2005-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0100437A2 (hu) | Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| HUP0500558A2 (hu) | Alacsony dózisú entecavir formuláció és eljárás előállítására | |
| DE68911891D1 (de) | Verwendung von Acetyl-L-carnitin zur Behandlung von Katarakt, sowie pharmazeutische Zusammensetzungen für eine derartige Behandlung. | |
| NO306894B1 (no) | Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet | |
| KR970061244A (ko) | 치매 치료용 약학 조성물 | |
| ATE193442T1 (de) | 3,4-diarylchromane zur behandlung von dermatitis | |
| PL360492A1 (en) | Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates | |
| DE69928806D1 (de) | (-)-pseudoephedrin als sympathomimetisches arzneimittel | |
| WO1997022354A3 (de) | Anwendung eines medikaments und verwendung eines stoffgemischs zur herstellung eines medikaments | |
| HUP0202525A2 (hu) | Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit | |
| JPH01261334A (ja) | アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法 | |
| ATE323481T1 (de) | Verwendung von propionyl-l-carnitin oder dessen pharmakologisch akzeptabler salze zur herstellung eines medikamentes zur behandlung von la peyronie's krankheit | |
| RU2002129298A (ru) | Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера | |
| ATE91890T1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
| CA2403674A1 (en) | The use of t3 for treating congestive heart failure | |
| ATE284696T1 (de) | Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten | |
| HUP0200129A2 (hu) | N-(3'4'-dimetoxi-cinnamoil)-antranilsav alkalmazása szívkoszorúér-műtéttel kapcsolatos cardiovascularis események megelőzésére vagy mérséklésére | |
| WO2001028541A3 (en) | Composition comprising sildenafil and l-arginine | |
| CO5160246A1 (es) | Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias | |
| MD1469G2 (ro) | Metodă de tratament al şocului combustional | |
| IT1258939B (it) | Analoghi esapeptidici lineari o ciclici delle tachichinine e loro sali farmaceuticamente accettabili, loro preparazione e composizioni farmaceutiche che li contengono | |
| ATE280584T1 (de) | Verwendung von beta interferon zur herstellung eines arzneimittels zur behandlung von ewings sarkom und eoe | |
| RU95109597A (ru) | Способ получения препарата "апсорин" для лечения псориаза и способ лечения псориаза |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1448184 Country of ref document: EP |